

## PRESS RELEASE

# Hansa Biopharma Presenting at the Pareto 16 Annual Healthcare Conference

Lund, Sweden, Monday 15 September, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma will be presenting at the 16<sup>th</sup> Annual Pareto Securities Healthcare Conference in Stockholm tomorrow, Tuesday 16 September, 10:40 CEST.

Aguiar-Lucander will also be participating in a panel discussion at 13:55 CEST on current industry dynamics that will explore business deals, healthcare system changes, and investor sentiment.

**Event details:** Hansa Biopharma AB Presentation

**Date and time:** Tuesday, September 16, 2025, 10:40 CEST

**Speaker:** Renée Aguiar-Lucander, CEO, Hansa Biopharma

**Event details:** Panel Discussion on Current Industry Dynamics

**Date and time:** Tuesday, September 16, 2025, 13:55 CEST

**Speaker:** Renée Aguiar-Lucander, CEO, Hansa Biopharma

For more information: [Events & Conferences | Pareto Securities : Pareto Securities](#)

--- ENDS ---

### Contacts for more information:

Evan Ballantyne, Chief Financial Officer  
[IR@hansabiopharma.com](mailto:IR@hansabiopharma.com)

Kerstin Falck, VP Global Corporate Affairs  
[media@hansabiopharma.com](mailto:media@hansabiopharma.com)

### Notes to editors

#### About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving

enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](http://www.hansabiopharma.com) and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.